ISTH 2017 Berlin revisited

ISTH Academy, Correspondence |Wolfram Ruf, 205271

What you don't know can kill you

ISTH Academy, Geoffrey Barnes, 205272

Correlates of plasma and platelet tissue factor pathway inhibitor, factor V, and Protein S

ISTH Academy, Alan Mast, 205273

Clinical outcome of patients with a vitamin K antagonist‐associated bleeding treated with prothrombin complex concentrate

ISTH Academy, Correspondence |Michiel Coppens, 205274

The role of scientific publishing in the development of early career investigators

ISTH Academy, Adam Cuker, 205275

Combined effects of two mutations in von Willebrand disease 2M phenotype

ISTH Academy, Adriana Woods, 205276

Early career professionals: A challenging road

ISTH Academy, Mandy Lauw, 205277

ISSUE INFORMATION

ISTH Academy, Session Speakers, 205278

Harold Ross Roberts, MD: inspirational mentor, consummate physician, superb scientist (1930‐2017)

ISTH Academy, Gilbert White II, 205279

A review of commercially available thrombin generation assays

ISTH Academy, Vera Ignjatovic, 205280

Lupus anticoagulant mixing tests for multiple reagents are more sensitive if interpreted with a mixing test‐specific cut‐off than index of circulating anticoagulant

ISTH Academy, Osamu Kumano, 205281

Balance, falls, and exercise: Beliefs and experiences in people with hemophilia: A qualitative study

ISTH Academy, Correspondence |Lorraine M. Flaherty, 205282

Novel therapies in thrombotic thrombocytopenic purpura

ISTH Academy, Spero Cataland, 205283

Global public awareness about atrial fibrillation

ISTH Academy, Aaron Mark Wendelboe, 205284

Current issues in diagnosis and treatment of von Willebrand disease

ISTH Academy, Veronica Flood, 205285

N‐methyl‐d‐aspartate receptor mediated calcium influx supports in vitro differentiation of normal mouse megakaryocytes but proliferation of leukemic cell lines

ISTH Academy, Maggie Kalev-Zylinska, 205286

Von Willebrand factor multimer quantitation for assessment of cardiac lesion severity and bleeding risk

ISTH Academy, Christopher Austin, 205287

Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism

ISTH Academy, Manuela Albisetti Pedroni, 205288

Platelets at the vascular interface

ISTH Academy, Wolfgang Bergmeier, 205289

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism

ISTH Academy, Correspondence |Dominique Lejeune, 205290

Acute infection as a trigger for incident venous thromboembolism: Results from a population‐based case‐crossover study

ISTH Academy, Gro Grimnes, 205291

Factor V‐short and protein S as synergistic tissue factor pathway inhibitor (TFPIα) cofactors

ISTH Academy, Björn Dahlbäck, 205292

Activity of factor XII‐Locarno

ISTH Academy, David Gailani, 205293

Randomized, double‐blind, placebo‐controlled, interventional phase IV investigation to assess the efficacy and safety of r‐hirudin gel (1120I.U) in patients with hematomas

ISTH Academy, Correspondence |Hani El‐Mowafi, 205294

Stay Coagulated and Join the ISTH Today

ISTH Academy, Session Speakers, 204867

Issue Information

ISTH Academy, Session Speakers, 204868

External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment

ISTH Academy, Ang Li, 204869

The ISTH Bleeding Assessment Tool and the risk of future bleeding

ISTH Academy, Maria Rosaria Fasulo, 204870

Joint effects of prothrombotic genotypes and body height on the risk of venous thromboembolism: the Tromsø study

ISTH Academy, Sigrid Braekkan, 204871

Evaluation of a microfluidic flow assay to screen for von Willebrand disease and low von Willebrand factor levels

ISTH Academy, Christopher Ng, 204872

The identification of at‐risk patients and prevention of venous thromboembolism in pediatric cancer: guidance from the SSC of the ISTH

ISTH Academy, Jay Michael S. Balagtas, 204873

Fibrin fuels fatty liver disease

ISTH Academy, Ton Lisman, 204874

Effects of low‐dose epinephrine on perioperative hemostasis and inflammatory reaction in major surgical operations: a randomized clinical trial

ISTH Academy, Liu Yang, 204875

Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers

ISTH Academy, Jerrold H. Levy, 204876

Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: a cohort study

ISTH Academy, Maarten B. Rookmaker, 204877

ADAMTS‐13 and von Willebrand factor: a dynamic duo

ISTH Academy, David Lane, 204878

Use of factor concentrates for the management of perioperative bleeding: guidance from the SSC of the ISTH

ISTH Academy, Anne Godier, 204879

What the neighbors say

ISTH Academy, Session Speakers, 204880

Natural antibodies to oxidation‐specific epitopes: innate immune response and venous thromboembolic disease

ISTH Academy, Sabine Eichinger, 204881

Targeting of C‐type lectin‐like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides: comment

ISTH Academy, Ulrike Flierl, 204882

Associations of activated coagulation factor VII and factor VIIa‐antithrombin levels with genome‐wide polymorphisms and cardiovascular disease risk

ISTH Academy, Russell Tracy, 204883

Receptor homodimerization plays a critical role in a novel dominant negative P2RY12 variant identified in a family with severe bleeding

ISTH Academy, Marie-Christine Morel-Kopp, 204884

Platelet rescue by macrophage depletion in obese ADAMTS‐13‐deficient mice at risk of thrombotic thrombocytopenic purpura

ISTH Academy, H Lijnen, 204885

Timing and severity of inhibitor development in recombinant versus plasma‐derived factor VIII concentrates: a SIPPET analysis

ISTH Academy, Flora Peyvandi, 204886

Aging of the venous valves as a new risk factor for venous thrombosis in the elderly: the BATAVIA study

ISTH Academy, Astrid Van Hylckama Vlieg, 204887

Characteristics and quality of oral anticoagulation treatment in pediatric patients in the Netherlands based on the CAPS cohort

ISTH Academy, Anthonius de Boer, 204888

SIPPET: insights into factor VIII immunogenicity

ISTH Academy, James O'Donnell, 204889

Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α‐chain crosslinking

ISTH Academy, Alisa Wolberg, 204890

Neighborhood watch

ISTH Academy, Session Speakers, 204891

Cancer and risk of cerebral venous thrombosis: a case–control study

ISTH Academy, Jonathan Coutinho, 204892

International collaborative study for the calibration of proposed International Standards for thromboplastin, rabbit, plain, and for thromboplastin, recombinant, human, plain

ISTH Academy, Ton van den Besselaar, 204893

Targeting of C‐type lectin‐like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides: reply

ISTH Academy, Cecile Oury, 204894

Elevated preoperative von Willebrand factor is associated with perioperative thrombosis in infants and neonates with congenital heart disease

ISTH Academy, Juan C. Ibla, 203869

Plasminogen activator inhibitor‐1 regulates the vascular expression of vitronectin

ISTH Academy, Jianbo Wu, 203870

Evaluation of the age‐dependent dosing recommendations for the administration of daily tinzaparin in children with thrombosis

ISTH Academy, Kathryn M. Musgrave, 203871

Retinoic acid receptor‐α regulates synthetic events in human platelets

ISTH Academy, Hansjorg Schwertz, 203872

The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran: comment

ISTH Academy, Luke Yip, 203873

Relationship between neighborhood socioeconomic status and venous thromboembolism: results from a population‐based study

ISTH Academy, Willem Lijfering, 203874

Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations

ISTH Academy, Jeffrey I. Weitz, 203875

Harold Ross Roberts, M.D: inspirational mentor, consummate physician, superb scientist (1930–2017)

ISTH Academy, Session Speakers, 203876

Antiphospholipid antibody‐induced cellular responses depend on epitope specificity : implications for treatment of antiphospholipid syndrome

ISTH Academy, Karl Lackner, 203877

Inherited thrombocytopenia caused by ANKRD26 mutations misdiagnosed and treated as myelodysplastic syndrome: report on two cases

ISTH Academy, Alessandro Pecci, 203878

Venous thromboembolism and risk of cancer in patients with rheumatoid arthritis

ISTH Academy, Alma B. Pedersen, 203879

Corrigendum

ISTH Academy, Session Speakers, 203880

Soluble fibrin causes an acquired platelet glycoprotein VI signaling defect: implications for coagulopathy

ISTH Academy, Scott Diamond, 203881

Long‐term mental wellbeing of adolescents and young adults diagnosed with venous thromboembolism: results from a multistage mixed methods study

ISTH Academy, Anette Hojen, 203882

What the neighbors say

ISTH Academy, Session Speakers, 203883

Soluble fibrin going for six

ISTH Academy, Samantha J. Montague, 203884

Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH

ISTH Academy, Dr. Alfonso Iorio, 203885

Is there also room for rational thought?

ISTH Academy, Session Speakers, 203886

Stay Coagulated and Join the ISTH Today

ISTH Academy, Session Speakers, 203887

Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice

ISTH Academy, Karen Vanhoorelbeke, 203888

Repeated measurements of carotid atherosclerosis and future risk of venous thromboembolism: the Tromsø Study

ISTH Academy, Birgit Sm�brekke, 203889

Tissue factor‐bearing microparticles and inflammation: a potential mechanism for the development of venous thromboembolism in cancer

ISTH Academy, Kathryn Date, 203890

Aerobic exercise training lowers platelet reactivity and improves platelet sensitivity to prostacyclin in pre‐ and postmenopausal women

ISTH Academy, Martina Helena Lundberg Slingsby, 203891

Issue Information

ISTH Academy, Session Speakers, 203892

Implementation of buffy‐coat‐derived pooled platelet concentrates for internal quality control of light transmission aggregometry: a proof of concept study

ISTH Academy, Harald Mangge, 203893

A large case series on surgical outcomes in congenital factor XIII deficiency patients in Iran

ISTH Academy, Mehran Karimi, 203894

No added value of the age‐adjusted D‐dimer cut‐off to the YEARS algorithm in patients with suspected pulmonary embolism

ISTH Academy, Frederikus Klok, 203895

Management of patients with bleeding disorders

ISTH Academy, Robert L. Reid & Nigel S. Key, 203690

Issue Information

ISTH Academy, Session Speakers, 203257

Minimal factor XIII activity level to prevent major spontaneous bleeds: comment

ISTH Academy, Majid Naderi, 203258

Human pancreatic tumors grown in mice release tissue factor‐positive microvesicles that increase venous clot size

ISTH Academy, Nigel mackman, 203259

Extended pharmacologic thromboprophylaxis in oncologic liver surgery is safe and effective

ISTH Academy, Thomas A. Aloia, 203260

Emil Alfred Loeliger (Zürich 28 June 1924–Leiden 29 May 2017)

ISTH Academy, Session Speakers, 203261

An αβ antagonist prevents thrombosis without causing Fc receptor γ‐chain IIa‐mediated thrombocytopenia

ISTH Academy, Tur-Fu Huang, 203262

Extramedullary hematopoiesis: a new feature of inherited thrombocytopenias?

ISTH Academy, Carlo Zaninetti, 203263

Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability

ISTH Academy, Jacqueline Halton, 203264

Reversal of apixaban anticoagulation by four‐factor prothrombin complex concentrates in healthy subjects: a randomized three‐period crossover study

ISTH Academy, Charles Frost, 203265

A novel protein C–factor VII chimera provides new insights into the structural requirements for cytoprotective protease‐activated receptor 1 signaling

ISTH Academy, Roger Preston, 203266

What the neighbors say

ISTH Academy, Session Speakers, 203273

Disease prevalence dependent failure rate in diagnostic management studies on suspected deep vein thrombosis: communication from the SSC of the ISTH

ISTH Academy, Frederikus Klok, 203274

Minimal factor XIII activity level to prevent major spontaneous bleeds: reply

ISTH Academy, Marzia Menegatti, 203275

Advanced cell‐based modeling of the royal disease: characterization of the mutated F9 mRNA

ISTH Academy, Jordi Barquinero, 203276

Predicting the risk of cancer after unprovoked venous thromboembolism: external validation of the RIETE score

ISTH Academy, Laurent Bertoletti, 203277

Thrombin‐activatable fibrinolysis inhibitor in human abdominal aortic aneurysm disease

ISTH Academy, Robert Ariens, 203278

Clinical course of patients with symptomatic isolated superficial vein thrombosis: the ICARO follow‐up study

ISTH Academy, Francesco Dentali, 203279

Coincidence

ISTH Academy, Session Speakers, 203280

Stay Coagulated and Join the ISTH Today

ISTH Academy, Session Speakers, 203281

A gain‐of‐function mutation in TNFRSF13B is a candidate for predisposition to familial or sporadic immune thrombocytopenia

ISTH Academy, GuangSen Zhang, 203282